ERBB2 and breast neoplasm: When examining survival outcomes by breast tumor subtypes regardless of race/ethnicity, patients with HER2‐E and TNBC had significantly shorter median survival time (P < 0.0001) compared to patients with luminal A and luminal B‐like tumors (Fig. 2).